Nominations of candidates for the 2017 Clunies Ross Awards will open mid August 2016.
Building Australia’s future industries will depend on adopting technological innovation to develop high-value products and services for a global market. Improving collaboration in Australia, between and within businesses and between business and publicly funded research, will significantly enhance innovation. Both domestic and international collaboration improves the productivity and competitiveness of Australian technology-based firms.
Over the past 25 years the Clunies Ross Awards (CRA) have recognised contributions by dedicated individuals to the application of technology for the benefit of Australia. In recognition of the complex nature of such activities, from 2016 the Clunies Ross Awards are awarded in three categories, with a single winner in each category.
The Australian Academy of Technology and Engineering (ATSE) administers the awards and they are awarded at the annual ATSE Innovation Dinner during the ATSE National Technology Challenges Dialogue in June.
Nominations of candidates for the 2017 Clunies Ross Awards will open mid August.
Information and Guidelines will be available soon.
If you wish to be notified when nominations are open, please sign up to the ATSE Clunies Ross email list.
For those who have played a leadership role in the translation to a commercial enterprise with a financially successful outcome of a technology based product or service in which they have personally had a significant input in the inventorship/development of the technology. Such a person would typically be the CEO or a senior manager and may be working in either an early stage or mature company environment, with demonstrated impact for Australia.
Typically this may be a person leading a start-up or early stage SME that is disrupting well established vendors through innovative use of new technologies.
Dr Saunders is an audiologist, innovator and an entrepreneur who has worked over the past 20 years to successfully disrupt hearing service provision in Australia, through challenging current business and pricing models, and improving technology in partnership with inventor Professor Peter Blamey.
Her initiatives have created approximately 100 high tech jobs in the past 20 years and culminated in the development of the IHearYou® self‐fit hearing aid system and remote tele‐audiology support model.
Dr Saunders is CEO of Blamey Saunders hears, which has commercialised these technologies to overcome cost and distance barriers and address premium hearing aid accessibility. Its mission is to improve hearing for four million Australians who would benefit from hearing aids but have not been helped by the existing audiology service model.
For those who have been responsible for a technology which has been commercialised most likely by licensing with a financially successful outcome.
Typically this could be a researcher or developer in a PFRO or private company who has successfully passed his or her product/invention/service to a third party to commercialise and has generated significant revenue to the person and /or organisation they are associated with.
Professor Smith is recognised internationally for her significant and sustained contributions to pain relief and pharmaceutical development through her pioneering breakthroughs in drug discovery and translation highlighted by discovery of a first-in-class novel therapeutic (EMA401) to treat neuropathic pain and chronic inflammatory pain. This drug avoids the central nervous system side-effects commonly produced by current pain medicines.
She is Executive Director of the Centre for Integrated Preclinical Drug Development (CIPDD) and until recently its commercial interface (TetraQ) and Professor of Pharmacy at The University of Queensland.
Professor Smith holds 11 patents in pain relief, with patented novel analgesics technologies licensed to three UQ spin-out companies including Spinifex Pharmaceuticals, formed by UniQuest Pty in 2005 to commercialize her AT2 receptor antagonist IP for the treatment of neuropathic pain, demonstrating a sustained and tenacious pursuit of translational research.
For those who have been responsible for the adoption of a technology of demonstrably significant potential, currently at a stage where the financial outcomes are yet to be realised and/or the benefits are of a measurable broad community nature.
Typically would be an early stage venture where the person is running substantial risks, enjoying early success but the outcome, financial or social good, is not yet assured or the financial outcome is in the form of industry development.
Professor Murphy, from the University of South Australia, has led an industry-focused research team specialising in thin-film coating science to develop a world first plastic automotive rear view mirror. With more than 10 years’ experience working in private industry, Professor Murphy has demonstrated outstanding research leadership across the industry/academia interface.
The Plastic Mirror is the world’s first lightweight, injection-compression moulded polycarbonate automotive rear-view mirror. Itis half the weight of traditional glass mirrors, distortion-free, shatterproof, resistant to UV weathering, abrasion resistant, withstands temperature extremes and offers design freedom and a simplified assembly process not possible with glass.
Professor Murphy and the project team – Dr Colin Hall, Associate Professor Drew Evans and Dr Kamil Zuber, Mr James Nicholson, Dr Scott Edwards, Mr Simon Field and Mr Bill Frank – have uniquely progressed Australia’s capability in advanced manufacturing through this product, which to date has seen more than 1.5 million mirror assemblies manufactured in Adelaide and exported to the USA.
Enhancing Australia's prosperity through technology and innovation